JP2024516416A5 - - Google Patents

Info

Publication number
JP2024516416A5
JP2024516416A5 JP2023566662A JP2023566662A JP2024516416A5 JP 2024516416 A5 JP2024516416 A5 JP 2024516416A5 JP 2023566662 A JP2023566662 A JP 2023566662A JP 2023566662 A JP2023566662 A JP 2023566662A JP 2024516416 A5 JP2024516416 A5 JP 2024516416A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
variable region
chain variable
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516416A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/050572 external-priority patent/WO2022226623A1/en
Publication of JP2024516416A publication Critical patent/JP2024516416A/ja
Publication of JP2024516416A5 publication Critical patent/JP2024516416A5/ja
Pending legal-status Critical Current

Links

JP2023566662A 2021-04-27 2021-04-27 腫瘍への免疫細胞浸潤を可能にするための方法 Pending JP2024516416A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2021/050572 WO2022226623A1 (en) 2021-04-27 2021-04-27 Method for allowing immune cells infiltration in tumors

Publications (2)

Publication Number Publication Date
JP2024516416A JP2024516416A (ja) 2024-04-15
JP2024516416A5 true JP2024516416A5 (cg-RX-API-DMAC7.html) 2024-05-13

Family

ID=83846453

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023566662A Pending JP2024516416A (ja) 2021-04-27 2021-04-27 腫瘍への免疫細胞浸潤を可能にするための方法
JP2023565954A Pending JP2024516818A (ja) 2021-04-27 2022-04-26 腫瘍への免疫細胞浸潤を可能にするための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023565954A Pending JP2024516818A (ja) 2021-04-27 2022-04-26 腫瘍への免疫細胞浸潤を可能にするための方法

Country Status (10)

Country Link
US (2) US20240199758A1 (cg-RX-API-DMAC7.html)
EP (2) EP4329801A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024516416A (cg-RX-API-DMAC7.html)
KR (2) KR20240014052A (cg-RX-API-DMAC7.html)
CN (2) CN117479955A (cg-RX-API-DMAC7.html)
AU (2) AU2021442702A1 (cg-RX-API-DMAC7.html)
CA (2) CA3173786A1 (cg-RX-API-DMAC7.html)
IL (2) IL307954A (cg-RX-API-DMAC7.html)
MX (2) MX2023012766A (cg-RX-API-DMAC7.html)
WO (2) WO2022226623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4329801A4 (en) * 2021-04-27 2025-05-14 Alethia Biotherapeutics Inc. Method for allowing immune cells infiltration in tumors
EP4475885A4 (en) * 2022-02-07 2026-02-18 Alethia Biotherapeutics Ulc POLYTHERAPY INTENDED FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN118914553B (zh) * 2024-07-22 2025-03-18 西安医学院第一附属医院 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1882A (en) 1872-12-11 Angus. Campbell A towel hanger
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
CA2928846A1 (en) * 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) * 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
EP4329801A4 (en) * 2021-04-27 2025-05-14 Alethia Biotherapeutics Inc. Method for allowing immune cells infiltration in tumors

Similar Documents

Publication Publication Date Title
KR102464774B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
KR102333658B1 (ko) 비-소세포 폐암을 치료하기 위한 항-b7-h1 및 항-ctla-4 항체
Gasser et al. Therapeutic antibodies in cancer therapy
JP7548924B2 (ja) がんの処置における増強された有効性のためのil-4/il-13経路阻害剤
WO2019140150A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
JP2023546679A (ja) がん治療における放射免疫療法とcd47遮断の併用
WO2025067400A1 (en) Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer
EP3880186B1 (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
JPWO2022270524A5 (cg-RX-API-DMAC7.html)
MXPA06008942A (es) Inmunoglobulinas anti-moleculas de adhesion a celulas epiteliales(epcam).
JP2023537222A5 (cg-RX-API-DMAC7.html)
AU2018271157A1 (en) Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
WO2022197900A1 (en) Methods for treating cancer with anti-ilt3 antibodies
WO2020216963A1 (en) Personalized immunotherapy for treatment of cancer
Dreanic et al. Gastric carcinoma at the era of targeted therapies
KR20200105825A (ko) 삼중 음성 유방암의 치료를 위한 pd-1 항체 및 아파티닙의 조합 치료의 용도
RU2836467C2 (ru) Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований
WO2018227280A1 (en) Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof
RU2026105366A (ru) Лечение рака легкого с помощью анти-pd-1 и химиотерапии
AU2024360430A1 (en) Anti-pd-1-based treatment before and after surgery
HK40112560A (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
CN120204383A (zh) 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
KR20230061499A (ko) Pd-1 저해제 투여에 의한 암 통증 치료 방법
HK40057287A (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
HK40057287B (en) Intralesional administration of pd-1 inhibitors for treating skin cancer